Integrin subunit beta 3 (ITGB3) mRNA (ITGB3 mRNA)

Integrin subunit beta 3 (ITGB3) mRNA is the transcript encoding the beta-3 subunit of the integrin receptor family, a group of transmembrane proteins essential for cell-matrix and cell-cell communication [1, 2]. This mRNA is translated into the CD61 protein, which forms two major heterodimeric complexes: alpha-IIb-beta-3 (GPIIb/IIIa), found predominantly on platelets, and alpha-v-beta-3, expressed on endothelial cells, osteoclasts, and various tumor cells [1, 5]. The GPIIb/IIIa complex is the primary mediator of platelet aggregation, making its protein product a major target for anti-thrombotic drugs such as Abciximab, Eptifibatide, and Tirofiban [3]. Additionally, the alpha-v-beta-3 complex is a key driver of tumor angiogenesis and metastasis, leading to the development of investigational antagonists like Cilengitide [5, 6]. While current clinical therapies target the protein, ITGB3 mRNA itself is an emerging target for gene-silencing technologies, including siRNAs and antisense oligonucleotides, aimed at treating advanced malignancies and inflammatory disorders [4, 6]. Mutations in the ITGB3 gene are the primary cause of Glanzmann thrombasthenia, a rare genetic disorder characterized by severe bleeding due to the absence of functional platelet aggregation [2, 7].

Other names

CD61 mRNAGP3A mRNAGPIIIa mRNAIntegrin beta-3 mRNAPlatelet membrane glycoprotein IIIa mRNA

Antagonism of the GPIIb/IIIa receptor complex to inhibit platelet aggregation; antagonism of the alpha-v-beta-3 receptor to inhibit angiogenesis and tumor cell migration; potential degradation of ITGB3 mRNA via RNA interference (siRNA) or antisense mechanisms to reduce protein expression.